skip to main
|
skip to sidebar
Tuesday, September 8, 2009
Good for Mice, at the Expense of Moths
Researchers are investigating the use of
insects for preclinical testing
, which could relieve mice and other common lab animals of their traditional duties.
--Paul Thomas
0 comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
QbD Twitter Updates
Search This Blog
Loading...
Blogs Related to QbD and Drug Development
On Pharma
QbD Viewpoint
dTC's Quality by Design Blog (Spanish)
QualityFirst from ASQ India
Ted Grasela's Pharma of the Future
Agile Clinical Development
BioIT Alliance
Chromosome
Data Mining Blog
EFPIA Blog
Emerson Global Life Sciences Blog
Life Sciences Developers and Architects
Related Content
PharmaQbD
Pharmaceutical Manufacturing
Innovative Medicines Initiative
Innovation.org (PhRMA)
ICH Home Page
About PharmaQbD Blog
Paul Thomas
Senior Editor of Pharmaceutical Manufacturing magazine, PharmaQbD.com, and PharmaManufacturing.com
View my complete profile
Subscribe To PharmaQbD Blog
Posts
Atom
Posts
Comments
Atom
Comments
Blog Archive
►
2010
(11)
►
April
(1)
We've Moved . . . Back to PharmaQbD.com
►
March
(1)
QbD Pioneer Afnan to Leave FDA
►
February
(2)
QbD Comes to India
Design for Six Sigma: A Model Partner for QbD
►
January
(7)
IFPAC: Analyze This
Is Tech Transfer Broken? Can the Principles of QbD...
QbD for Biotech in Three Parts
QbD News Delivered to Your Desk
Looking for a Few Good Authors: QbD "From Theory t...
Tufts Center: Approval Times Have Dropped, But Is ...
Visualizing the Golden Batch with S88
▼
2009
(75)
►
December
(1)
Quality Risk Management: Looking North
►
November
(7)
In the EU, Funding for Those Who Strive to Elimina...
A-Mab Case Study: Read It and Weep?
GSK's Peterson Has Just What Your Design Space Nee...
Are You Innovating and Imaginating All By Yourself...
Looking Ahead to IFPAC
The Henry Ford of Drug Development? Have We Heard ...
Merck's Clark: Merger with S-P Will Increase Not J...
►
October
(11)
Push vs. Pull: Finding Better Ways to Incentivize ...
Treasure Trove: Merck, Lilly, Amgen, Pfizer, and M...
Should We Call It an ELNLIMS?
Lessons Learned from 20 Years of Drug Development
Pharma IT Moves Further Into the SaaS Era
The Challenges of Developing Alzheimer's Therapies...
Where Lies QbD's Competitive Advantage?
Studying Dogs Alongside Humans, to Develop Cancer ...
QbD for Generics: Considerations and Questions
S-P'S Hassan: Small Developers Losing Clout, and R...
What Lessons Will We Take Away from H1N1 Vaccine D...
▼
September
(10)
What's on Your QbD Calendar?
Global Outsourcing of Clinical Trials: Patient Con...
One Man's Experience: Integrating SQL*LIMS with an...
ICH Guidelines Show Their Age (and Difficulty)
FDA Initiates Study of QbD for Lyo Protein Product...
Good for Mice, at the Expense of Moths
U.S. vs. EU: Who's Better at Getting Drugs to Mark...
What is Your Favorite QbD Analytical Tool?
Drug Development, an Interactive Tour
Got QbD Education? Tell Us About It
►
August
(13)
EFPIA Ready to Roll Out Its QbD "Concept Cars"
It's (Un)Official: QbD Moving at a Snail's Pace
Tech Transfer: Good Science and a Common Sense App...
Can Microsoft Fix What Ails QbD Efforts?
For QbD and PAT, Are You Part of the In-Crowd (or ...
Oracle's Balakrishnan: Towards an Integrated QbD
What is Your QbD Pain Point?
FAQ's from ICH: What's Your Take?
FAQ's from the ICH Quality Implementation Working ...
Webinar: Constructing a Design Space from a Mechan...
►
July
(26)
►
June
(7)
0 comments:
Post a Comment